Related Experiment Video
Updated: May 6, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Efficacy and Safety of a Novel Oral Rehydration Solution (ORS) in Managing Diarrhea and Dehydration: A Randomized
Bridreth Khokhare1, Nutan Agrawal2, Mohammed Siddique2
1Department of Research and Development, Mystical Biotech Pvt. Ltd., Bengaluru, IND.
Background:
Acute diarrhea is a leading cause of dehydration-related morbidity. Oral rehydration solution (ORS) remains the cornerstone of treatment, while probiotics have shown additional gut health benefits. This study evaluated the efficacy and safety of a novel probiotic-enriched ORS compared with a standard ORS in Indian patients with acute diarrhea.
Methods:
In this randomized, parallel-group study, patients with diarrhea were enrolled and assigned to receive either novel ORS or traditional ORS. Treatment was administered for five days, followed by a four-day observation period and a safety follow-up call. Group 1 received the novel ORS (200 mL/day) for five days, and Group 2 received traditional ORS (200 mL/day) for a similar duration. Efficacy outcomes measured included resolution of diarrhea, time to recovery, patient-reported satisfaction and preference, and Clinical Global Impression-Improvement (CGI-I) score.
Results:
In this randomized, parallel-group study, 60 patients with diarrhea were enrolled and assigned (3:1) to receive either novel ORS (n = 45) or traditional ORS (n = 15). Both groups showed clinical improvement; however, the novel ORS group demonstrated faster resolution. By visit 3, the mean diarrhea episodes were 0.4 (0.62) in the novel ORS group, while 0.9 (0.86) in the traditional group. Higher satisfaction was reported in the novel ORS group (42.2% "very satisfied") along with quicker improvement on the CGI-I score (mean score 1.3 vs. 1.9; p = 0.0120).
Conclusion:
The novel ORS containing probiotics showed faster symptom resolution, higher patient satisfaction, and comparable safety, supporting its potential as a preferred treatment option for diarrhea management.
More Related Videos
Related Concept Videos
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Regulation of Water Intake
Drug Delivery Systems: Different Types
Cholera

